LEGNNasdaqPharmaceutical PreparationsFiscal year ends December 31
Legend Biotech Corp
Financials through Q4 FY2025, quarter ended Dec 31, 2025Last filing: 20-F on Mar 10, 2026
$18.65+0.17 (+0.92%)
Close on Oct 19, 2026
- Market cap
- $6.89B
- P/E (TTM)
- –
- Dividend yield
- –
Legend Biotech statistics
Financials through Dec 31, 2025, price as of Oct 19, 2026, median of Pharmaceutical Preparations companies for comparison
Valuation
| Measure | Legend Biotech | Industry median |
|---|---|---|
| Market Cap | $3.45B | $164.85M |
| Enterprise Value | $2.87B | $87.06M |
| PS Ratio | 3.35 | 3.60 |
Enterprise value
| Measure | Legend Biotech | Industry median |
|---|---|---|
| EV / Sales | 2.79 | 2.43 |
Income (trailing twelve months)
| Measure | Legend Biotech | Industry median |
|---|---|---|
| Revenue | $1.03B | $57.94M |
| Gross Profit | $631.80M | $90.47M |
| Operating Income | -$136.50M | -$21.44M |
| Pretax Income | -$282.60M | -$14.45M |
| EBITDA | -$136.50M | -$16.91M |
Margins
| Measure | Legend Biotech | Industry median |
|---|---|---|
| Gross Margin | 61.4% | 52.3% |
| Operating Margin | -13.3% | -44.5% |
| Pretax Margin | -27.5% | -13.0% |
| EBITDA Margin | -13.3% | -31.3% |
| FCF Margin | -12.5% | -8.85% |
Returns
| Measure | Legend Biotech | Industry median |
|---|---|---|
| Return on Invested Capital (ROIC) | -10.2% | -32.0% |
| Return on Capital Employed (ROCE) | -12.4% | -37.8% |
Growth
| Measure | Legend Biotech | Industry median |
|---|---|---|
| Revenue Growth (YoY) | 64.0% | 6.01% |
| Revenue Growth (3Y CAGR) | 106.4% | 2.25% |
| Revenue Growth (5Y CAGR) | 68.8% | 6.42% |
Balance sheet
| Measure | Legend Biotech | Industry median |
|---|---|---|
| Cash & Short-Term Investments | $901.90M | $62.42M |
| Total Debt | $319.10M | $120.13M |
| Net Cash (Debt) | $582.80M | $15.68M |
| Net Cash Per Share | $1.58 | $0.66 |
| Working Capital | $610.70M | $75.77M |
Financial position
| Measure | Legend Biotech | Industry median |
|---|---|---|
| Current Ratio | 1.96 | 3.30 |
| Quick Ratio | 1.44 | 2.39 |
| Interest Coverage | -6.38 | -7.12 |
Cash flow (trailing twelve months)
| Measure | Legend Biotech | Industry median |
|---|---|---|
| Operating Cash Flow | -$100.20M | -$12.35M |
| Capital Expenditures | -$28.60M | -$1.06M |
| Free Cash Flow | -$128.80M | -$20.28M |
| FCF Per Share | -$0.35 | -$0.42 |
Efficiency
| Measure | Legend Biotech | Industry median |
|---|---|---|
| Asset Turnover | 0.60 | 0.38 |
| Inventory Turnover | 14.21 | 2.67 |
| Revenue Per Employee | $354.79K | $398.96K |
| Employee Count | 2,900 | 74 |
Dividends and yields
| Measure | Legend Biotech | Industry median |
|---|---|---|
| FCF Yield | -3.73% | -9.07% |
Shares
| Measure | Legend Biotech | Industry median |
|---|---|---|
| Shares Outstanding | 369,886,000 | 58,179,650 |
| Shares Change (YoY) | 0.80% | 11.1% |
| Float | 368,014,000 | 49,173,100 |
| Shares Held by Insiders | 0.51% | 11.6% |
| Shares Held by Institutions | 28.4% | 59.4% |
Taxes
| Measure | Legend Biotech | Industry median |
|---|---|---|
| Income Tax | $14.20M | $91.50K |
Scores
| Measure | Legend Biotech | Industry median |
|---|---|---|
| Altman Z-Score | 3.59 | -0.24 |
Calculated by StockData from Legend Biotech's SEC filings and the latest closing price. Hover a measure to see its formula. The grey column is the median of companies in the same industry group (two-digit SIC code); green or red marks a better or worse value than that median.